EMEA-001710-PIP03-17-M03 - paediatric investigation plan
Ozanimod (hydrochloride)
PIPHuman
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com
Tel: +44 1423 53 3610
P/0233/2021 : EMA decision of 8 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for ozanimod (hydrochloride) (Zeposia) (EMEA-001710-PIP03-17-M03)